Multiple Sclerosis Walking Scale-12 (MSWS-12)
Multiple Sclerosis Walking Scale-12 · Also known as: MS Walking Scale-12, MSWS
The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation. Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
MSWS-12 is ideal when brief assessment of MS walking impact is needed: clinical trials of therapies targeting mobility (rehabilitation, exercise, walking-specific treatments), routine clinical monitoring in MS clinics to track walking-related disability, longitudinal cohort studies examining predictors of walking decline, comparative effectiveness research of mobility interventions, and patient-reported outcomes surveillance. It complements objective gait measures (Timed 25-Foot Walk, 6-Minute Walk Test) by capturing subjective walking experience. It is less suitable when non-walking MS patients must be assessed (use broader QoL scales like MSQOL-54 instead) or when only objective gait speed is the outcome of interest.
Strengths & limitations
- Extremely brief (12 items, 3-5 minutes) and practical for routine clinical use and serial monitoring without substantial respondent burden
- Highly responsive to change—sensitive to detecting meaningful improvements in walking with rehabilitation or treatment
- Strong psychometric properties: demonstrated validity, reliability, and minimal floor/ceiling effects in diverse MS populations across disease courses
- Patient-centered measurement captures subjective walking experience and functional limitation beyond objective gait speed
- Widely adopted in MS research and clinical practice worldwide; extensively translated and validated in multiple languages
- Scores range 0-100 with higher=worse, which is opposite to most QoL scales and can be counterintuitive; scoring transformation must be applied correctly
- Not suitable for non-ambulatory MS patients (cannot walk at baseline); does not measure wheelchair/assistive device use experience
- May show ceiling effect in very early MS with minimal walking limitation (many score near 0)
- Unidimensional structure means it does not differentiate causes of limitation (e.g., weakness vs. spasticity vs. fatigue); supplements with targeted examination needed
Frequently asked
Does a high MSWS-12 score mean good walking or bad walking?
High MSWS-12 score means WORSE walking limitation. On the 0-100 scale, 0-20 = minimal limitation (good), 81-100 = very severe limitation (bad). This is opposite to most QoL scales (e.g., MSQOL-54, SF-36) where high=better. Always check the scale direction when comparing measures.
How much MSWS-12 change is clinically meaningful?
A change of 4-5 points on the 0-100 scale is considered the minimal clinically important difference (MCID). So an improvement (decrease) from baseline 50 to 45 is meaningful; a change to 48 might not be. In clinical trials, effect sizes and between-group differences are more informative than individual point changes.
Should I use MSWS-12 or Timed 25-Foot Walk test?
MSWS-12 measures patient-perceived walking limitation; Timed 25-Foot Walk measures objective gait speed. Both are valuable and often used together: T25FW for objective impairment, MSWS-12 for subjective impact. Some patients with slow gait report minimal limitation; others with faster gait report substantial limitation. Both capture important aspects. Use MSWS-12 for clinical monitoring of QoL impact; use T25FW to objectively track gait speed changes.
Can MSWS-12 be used in wheelchair-using MS patients?
No. MSWS-12 measures walking limitation experience and is designed for patients who walk (with or without assistive devices). For non-ambulatory patients, use broader MS QoL scales (MSQOL-54) or wheelchair-specific mobility measures. If a patient transitions from walking to wheelchair during longitudinal follow-up, MSWS-12 becomes inapplicable after that transition; switch to alternative measures at that point.
Sources
- Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36. DOI: 10.1212/WNL.60.1.31 ↗
How to cite this page
ScholarGate. (2026, June 3). Multiple Sclerosis Walking Scale-12. ScholarGate. https://scholargate.app/en/neurology/msws-12
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
Compare side by side →